BioXcel Therapeutics is trading 19.96% down now at $0.13 after Nasdaq confirmed delisting following its voluntary Chapter 11 bankruptcy filing.
- The bankruptcy began on August 27, 2026, alongside an agreement to sell substantially all assets to Teva.
- Delisting and severe recovery uncertainty are the primary company-specific catalysts; broader risk-off conditions and biotechnology weakness may add pressure.